Yoon, N. Jang, A.-K. Seo, Y. Jung, B.H. 2024-01-19T13:03:35Z 2024-01-19T13:03:35Z 2022-02-17 2021-12 2218-1989 https://pubs.kist.re.kr/handle/201004/115962 The metabolomics approach represents the last downstream phenotype and is widely used in clinical studies and drug discovery. In this paper, we outline recent advances in the metabolomics research of autoimmune diseases (ADs) such as rheumatoid arthritis (RA), multiple sclerosis (MuS), and systemic lupus erythematosus (SLE). The newly discovered biomarkers and the metabolic mechanism studies for these ADs are described here. In addition, studies elucidating the metabolic mechanisms underlying these ADs are presented. Metabolomics has the potential to contribute to pharmacotherapy personalization; thus, we summarize the biomarker studies performed to predict the personalization of medicine and drug response. ？ 2021 by the authors. Licensee MDPI, Basel, Switzerland. English Multidisciplinary Digital Publishing Institute (MDPI) Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis Article 10.3390/metabo11120812 1 Metabolites, v.11, no.12 Metabolites 11 12 Y scie scopus 000743070000001 2-s2.0-85121830494 Biochemistry & Molecular Biology Biochemistry & Molecular Biology Article STANDARDIZED FRANKINCENSE EXTRACT CEREBROSPINAL-FLUID T-CELLS ACID-METABOLISM IMMUNE-SYSTEM DRUG RESPONSE BIOMARKERS NMR SIGNATURES METHOTREXATE Autoimmune disease Metabolomics Pharmacometabolomics